AbbVie Announced SKYRIZI Vs STELARA Head-to-Head Study In Crohn's Disease Met All Primary And Secondary Endpoints
Portfolio Pulse from Charles Gross
AbbVie has presented positive results from the Phase 3 SEQUENCE study that evaluated the efficacy and safety of risankizumab (SKYRIZI) compared to ustekinumab (STELARA) in patients with moderately to severely active Crohn's disease. The study met all primary and secondary endpoints.
October 15, 2023 | 3:29 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The positive results from the Phase 3 SEQUENCE study could potentially boost AbbVie's market position in the treatment of Crohn's disease.
The positive results from the Phase 3 SEQUENCE study indicate that SKYRIZI is effective in treating Crohn's disease. This could potentially lead to increased sales and market share for AbbVie in the Crohn's disease treatment market, positively impacting its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100